This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosenthal, T. Articles by Cohen, A. Search for Related Content PubMed PubMed Citation Articles by Rosenthal, T. Articles by Cohen, A.

(Hypertension. 1997;29:1260-1264.)
© 1997 American Heart Association, Inc.

Articles

Effects of Enalapril, Losartan, and Verapamil on Blood Pressure and Glucose Metabolism in the Cohen-Rosenthal Diabetic Hypertensive Rat

Talma Rosenthal; Yael Erlich; Eliezer Rosenmann; ; Aharon Cohen

From the Chorley Institute of Hypertension, Chaim Sheba Medical Center, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University (T.R., Y.E.), and Departments of Medicine and Pathology, The Hebrew University–Hadassah Medical School, Jerusalem (E.R., A.C.) (Israel).

Correspondence to Prof Talma Rosenthal, Chorley Institute of Hypertension, Chaim Sheba Medical Center, Tel Hashomer 65261 Israel.

Abstract We undertook the present study to examine the effect of the angiotensin-converting enzyme inhibitor enalapril, the angiotensin II antagonist losartan, and calcium antagonist verapamil on systolic pressure and spontaneous blood glucose levels in rats from the Cohen-Rosenthal diabetic hypertensive strain. Genetic hypertension and diabetes developed in this strain after crossbreeding of Cohen diabetic and spontaneously hypertensive rats. The new rat strain was fed their usual copper-poor sucrose diet, which is essential for the development of this model, and for 4 weeks received either enalapril, losartan, or verapamil. Systolic pressure was reduced significantly compared with controls in all treated groups. Chronic treatment with enalapril or verapamil, but not with losartan, succeeded in lowering spontaneous blood glucose, indicating improved diabetic control. Data suggest that angiotensin-converting enzyme inhibition by enalapril, but not angiotensin II antagonism by losartan, can improve glucose metabolism in addition to its hypotensive effect in a genetic diabetic hypertensive rat strain. This confirms that the drop in glucose with converting enzyme inhibition is highly dependent on bradykinin accumulation. Data further suggest that calcium channel blockade by verapamil can also improve glucose metabolism. The question remains whether the reduction in glucose by verapamil was a result of inhibition of glucogenesis.

Key Words: diabetes mellitus, experimental • rats • enalapril • losartan • verapamil

This article has been cited by other articles:

				T. Rosenthal, E. Rosenmann, D. Tomassoni, and F. Amenta Effect of Lercanidipine on Kidney Microanatomy in Cohen-Rosenthal Diabetic Hypertensive Rats Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 145 - 152. [Abstract] [PDF]

				F. Amenta, E. Peleg, D. Tomassoni, M. Sabbatini, and T. Rosenthal Effect of Treatment With Lercanidipine on Heart of Cohen-Rosenthal Diabetic Hypertensive Rats Hypertension, June 1, 2003; 41(6): 1330 - 1335. [Abstract] [Full Text] [PDF]

				The DIRECT Programme Study Group and N. Chaturvedi The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design Journal of Renin-Angiotensin-Aldosterone System, December 1, 2002; 3(4): 255 - 261. [Abstract] [PDF]

				S. A Doggrell and L. Brown Rat models of hypertension, cardiac hypertrophy and failure Cardiovasc Res, July 1, 1998; 39(1): 89 - 105. [Full Text] [PDF]

				L. V. d'Uscio, S. Shaw, M. Barton, and T. F. Luscher Losartan but Not Verapamil Inhibits Angiotensin II–Induced Tissue Endothelin-1 Increase : Role of Blood Pressure and Endothelial Function Hypertension, June 1, 1998; 31(6): 1305 - 1310. [Abstract] [Full Text] [PDF]